We are live on ! Find out more

127 hedge funds and large institutions have $1.84B invested in Insmed in 2018 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 55 increasing their positions, 33 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 33

7.68% more ownership

Funds ownership: 99.11%106.79% (+7.7%)

0% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 21

2% less funds holding

Funds holding: 129127 (-2)

17% less funds holding in top 10

Funds holding in top 10: 65 (-1)

22% less capital invested

Capital invested by funds: $2.37B → $1.84B (-$524M)

66% less call options, than puts

Call options by funds: $8.16M | Put options by funds: $24.1M

Holders
127
Holders Change
-2
Holders Change %
-1.55%
% of All Funds
2.91%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.11%
New
21
Increased
55
Reduced
33
Closed
21
Calls
$8.16M
Puts
$24.1M
Net Calls
-$15.9M
Net Calls Change
-$17M
Name Holding Trade Value Shares
Change
Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$9.39M -$353K -13,406 -3%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$8.62M -$991K -37,637 -9%
Charles Schwab
28
Charles Schwab
California
$8.59M +$521K +19,782 +5%
CWG
29
C WorldWide Group
Denmark
$8.39M -$509K -19,345 -5%
Goldman Sachs
30
Goldman Sachs
New York
$7.78M +$1.15M +43,693 +14%
BG
31
Bellevue Group
Switzerland
$7.53M +$8.8M +334,489 New
Ameriprise
32
Ameriprise
Minnesota
$7.27M +$970K +36,842 +13%
D.E. Shaw & Co
33
D.E. Shaw & Co
New York
$6.62M -$5.61M -213,347 -42%
JGC
34
J. Goldman & Co
New York
$5.97M +$6.45M +245,229 +1,233%
RHJA
35
Rice Hall James & Associates
California
$5.89M +$6.89M +261,712 New
TD Asset Management
36
TD Asset Management
Ontario, Canada
$5.85M -$23.7K -900 -0.3%
TA
37
Teachers Advisors
New York
$5.84M +$92.7K +3,521 +1%
TCIM
38
TIAA CREF Investment Management
New York
$5.5M -$8.24K -313 -0.1%
PC
39
PointState Capital
New York
$5.09M +$5.95M +226,000 New
JP Morgan Chase
40
JP Morgan Chase
New York
$4.93M +$305K +11,604 +6%
Hudson Bay Capital Management
41
Hudson Bay Capital Management
Connecticut
$4.28M +$1.84M +70,000 +58%
AllianceBernstein
42
AllianceBernstein
Tennessee
$4.09M +$763K +29,000 +19%
ACM
43
Asymmetry Capital Management
California
$3.65M +$103K +3,908 +2%
Principal Financial Group
44
Principal Financial Group
Iowa
$3.5M -$20K -759 -0.5%
California Public Employees Retirement System
45
California Public Employees Retirement System
California
$3.32M +$1.61M +61,000 +70%
Invesco
46
Invesco
Georgia
$3.1M +$144K +5,484 +4%
Wellington Management Group
47
Wellington Management Group
Massachusetts
$3.09M +$1.46M +55,582 +68%
Swiss National Bank
48
Swiss National Bank
Switzerland
$2.86M +$192K +7,300 +6%
UBS Group
49
UBS Group
Switzerland
$2.65M +$2.55M +96,897 +469%
California State Teachers Retirement System (CalSTRS)
50
California State Teachers Retirement System (CalSTRS)
California
$2.62M -$108K -4,085 -3%

INSM Hedge Fund Activity: Q1 2018 in Review

127 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Insmed (INSM) for Q1 2018, worth a combined $1.84B — down 22% from $2.37B a quarter earlier.

Fund positioning in INSM was balanced in Q1 2018: 21 funds opened new positions, 21 closed out, 55 added to existing stakes and 33 trimmed.

The largest buyer was OrbiMed, adding an estimated $37.7M. The largest seller was T. Rowe Price Associates, cutting an estimated $11.8M.

  • 127 institutional investors held Insmed (INSM) as of Q1 2018, down from 129 in Q4 2017.
  • Funds reported $1.84B of Insmed stock for Q1 2018, down 22% quarter-over-quarter.
  • 21 funds opened new Insmed positions in Q1 2018 and 21 closed out, a net change of 0 holders.
  • The largest Insmed buyer in Q1 2018 was OrbiMed, an estimated $37.7M added.
  • The largest Insmed seller in Q1 2018 was T. Rowe Price Associates, an estimated $11.8M sold.

Based on aggregated 13F filings for Q1 2018.